Werewolf Therapeutics Inc... (HOWL)
0.79
-0.12 (-13.42%)
At close: Apr 03, 2025, 3:59 PM
0.80
1.30%
After-hours: Apr 03, 2025, 07:23 PM EDT
-13.42% (1D)
Bid | 0.79 |
Market Cap | 35.53M |
Revenue (ttm) | n/a |
Net Income (ttm) | n/a |
EPS (ttm) | -1.63 |
PE Ratio (ttm) | -0.49 |
Forward PE | -1.01 |
Analyst | Buy |
Ask | 0.8 |
Volume | 506,956 |
Avg. Volume (20D) | 267,491 |
Open | 0.88 |
Previous Close | 0.91 |
Day's Range | 0.79 - 0.88 |
52-Week Range | 0.79 - 6.89 |
Beta | 0.48 |
About HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated In...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 30, 2021
Employees 46
Stock Exchange NASDAQ
Ticker Symbol HOWL
Website https://werewolftx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for HOWL stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 909.21% from the latest price.
Stock ForecastsNext Earnings Release
Werewolf Therapeutics Inc. is scheduled to release its earnings on May 2, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription